Background: 2Lþ overall response rates (ORRs) with PD-(L)1 inhibitors in patients (pts) with advanced NSCLC range from 12% to 19% (PD-L1 unselected), and median PFS ranges from 2.3 to 4.0 mo. Inhibiting the transforming growth factor b (TGF-b) pathway, which promotes tumor immunosuppression, may enhance the response to PD-(L)1 therapy. M7824 is an innovative first-in-class bifunctional fusion protein composed of a human IgG1 monoclonal antibody against PD-L1 fused with 2 extracellular domains of TGF-bRII (a TGF-b "trap"). Methods: Pts with advanced NSCLC unselected for PD-L1 who progressed after 1L standard treatment (no prior immunotherapy) were randomized to receive M7824 500 or 1200 mg (n ¼ 40 each) q2w until disease progression, unacceptable toxicity or trial withdrawal in this expansion cohort of the ongoing, phase 1 trial NCT02517398. The primary objective is to assess BOR per RECIST v1.1; other objectives are dose exploration and safety/tolerability. Tumor cell PD-L1 expression (Ab clone 73-10 [80% is comparable to 50% with 22C3]) was evaluable in 75 pts. Results: As of March 12, 2018, 80 pts received M7824 for a median of 11.9 (range, 2-66.1) wk, with a median follow-up of 51.1 wk; 10 pts remain on treatment. Investigator-assessed confirmed ORR was 27.5% at 1200 mg and 20% at 500 mg. Clinical activity was observed across PD-L1 subgroups (Table) ; ORR was 40.7% in PD-L1 þ (1%) and 71.4% in PD-L1-high (80%) pts at 1200 mg. The most common treatment-related adverse events (TRAEs) were pruritus (20%), maculopapular rash (18.8%), decreased appetite (12.5%) and asthenia (11.3%). Grade 3 TRAEs occurred in 23 pts (28.8%); 8 pts (500 mg, n ¼ 2; 1200 mg, n ¼ 6) discontinued treatment due to TRAEs. No treatment-related deaths occurred. Table: 1463P ORR, n/N; % 500 mg 1200 mg Total
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